Radiotherapy deep dive, turnover in Congress & BioNTech’s latest: a BioCentury podcast
What’s behind radiopharmaceuticals’ resurgence. Lawmakers who left their mark on biotech. BioNTech goes to London.
By Jeff Cranmer, Executive Editor
November 28, 2023 12:12 AM UTC
Radiopharmaceuticals have experienced a resurgence over the past decade, with a series of approvals, billion-dollar deals and growing sales. On the latest BioCentury This Week podcast, Director of Biopharma Intelligence Karen Tkach Tuzman previews her upcoming analysis of the space, discussing the multidimensional nature of the technology’s evolution, and the field’s next-wave targets behind PSMA and SSTR2.
BioCentury’s editors also discuss the legacies of two U.S. lawmakers who won’t stand for re-election, Reps. Anna Eshoo (D-Calif.) and Michael Burgess (R-Texas); the latest move by BioNTech SE (NASDAQ:BNTX) to grow its global footprint; and the November rise of the SPDR S&P Biotech ETF (XBI).
